API SUPPLIERS

API Suppliers

23

US DMFs Filed

4

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

4

Other Suppliers

20

API REF. PRICE (USD / KG)

17,354

API Market Place

7

INTERMEDIATES

38

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

20

USFDA Exclusivities

4

DIGITAL CONTENT

Blog #PharmaFlow

3

News

129

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Blog

Full Screen View

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-Myers Squibb acquiring New Jersey-based cancer drug company Celgene in a US$ 74 billion deal announced on January 3, 2019. After factoring in debt, the deal value ballooned to about US$ 95 billion, which according to data compiled by Refinitiv, made it the largest healthcare deal on record. In the summer, AbbVie Inc, which sells the world’s best-selling drug Humira, announced its acquisition of Allergan Plc, known for Botox and other cosmetic treatments, for US$ 63 billion. While the companies are still awaiting regulatory approval for their deal, with US$ 49 billion in combined 2019 revenues, the merged entity would rank amongst the biggest in the industry. View Our Interactive Dashboard on Top drugs by sales in 2019 (Free Excel Available) The big five by pharmaceutical sales — Pfizer, Roche, J&J, Novartis and Merck Pfizer continued to lead companies by pharmaceutical sales by reporting annual 2019 revenues of US$ 51.8 billion, a decrease of US$ 1.9 billion, or 4 percent, compared to 2018. The decline was primarily attributed to the loss of exclusivity of Lyrica in 2019, which witnessed its sales drop from US$ 5 billion in 2018 to US$ 3.3 billion in 2019. In 2018, Pfizer’s then incoming CEO Albert Bourla had mentioned that the company did not see the need for any large-scale M&A activity as Pfizer had “the best pipeline” in its history, which needed the company to focus on deploying its capital to keep its pipeline flowing and execute on its drug launches. Bourla stayed true to his word and barring the acquisition of Array Biopharma for US$ 11.4 billion and a spin-off to merge Upjohn, Pfizer’s off-patent branded and generic established medicines business with Mylan, there weren’t any other big ticket deals which were announced. The Upjohn-Mylan merged entity will be called Viatris and is expected to have 2020 revenues between US$ 19 and US$ 20 billion and could outpace Teva to become the largest generic company in the world, in term of revenues. Novartis, which had followed Pfizer with the second largest revenues in the pharmaceutical industry in 2018, reported its first full year earnings after spinning off its Alcon eye care devices business division that had US$ 7.15 billion in 2018 sales. In 2019, Novartis slipped two spots in the ranking after reporting total sales of US$ 47.4 billion and its CEO Vas Narasimhan continued his deal-making spree by buying New Jersey-headquartered The Medicines Company (MedCo) for US$ 9.7 billion to acquire a late-stage cholesterol-lowering therapy named inclisiran. As Takeda Pharmaceutical Co was busy in 2019 on working to reduce its debt burden incurred due to its US$ 62 billion purchase of Shire Plc, which was announced in 2018, Novartis also purchased the eye-disease medicine, Xiidra, from the Japanese drugmaker for US$ 5.3 billion. Novartis’ management also spent a considerable part of 2019 dealing with data-integrity concerns which emerged from its 2018 buyout of AveXis, the gene-therapy maker Novartis had acquired for US$ 8.7 billion. The deal gave Novartis rights to Zolgensma, a novel treatment intended for children less than two years of age with the most severe form of spinal muscular atrophy (SMA). Priced at US$ 2.1 million, Zolgensma is currently the world’s most expensive drug. However, in a shocking announcement, a month after approving the drug, the US Food and Drug Administration (FDA) issued a press release on data accuracy issues as the agency was informed by AveXis that its personnel had manipulated data which the FDA used to evaluate product comparability and nonclinical (animal) pharmacology as part of the biologics license application (BLA), which was submitted and reviewed by the FDA. With US$ 50.0 billion (CHF 48.5 billion) in annual pharmaceutical sales, Swiss drugmaker Roche came in at number two position in 2019 as its sales grew 11 percent driven by its multiple sclerosis medicine Ocrevus, haemophilia drug Hemlibra and cancer medicines Tecentriq and Perjeta. Roche’s newly introduced medicines generated US$ 5.53 billion (CHF 5.4 billion) in growth, helping offset the impact of the competition from biosimilars for its three best-selling drugs MabThera/Rituxan, Herceptin and Avastin. In late 2019, after months of increased antitrust scrutiny, Roche completed its US$ 5.1 billion acquisition of Spark Therapeutics to strengthen its presence in gene therapy. Last year, J&J reported almost flat worldwide sales of US$ 82.1 billion. J&J’s pharmaceutical division generated US$ 42.20 billion and its medical devices and consumer health divisions brought in US$ 25.96 billion and US$ 13.89 billion respectively. Since J&J’s consumer health division sells analgesics, digestive health along with beauty and oral care products, the US$ 5.43 billion in consumer health sales from over-the-counter drugs and women’s health products was only used in our assessment of J&J’s total pharmaceutical revenues. With combined pharmaceutical sales of US$ 47.63 billion, J&J made it to number three on our list. While the sales of products like Stelara, Darzalex, Imbruvica, Invega Sustenna drove J&J’s pharmaceutical business to grow by 4 percent over 2018, the firm had to contend with generic competition against key revenue contributors Remicade and Zytiga. US-headquartered Merck, which is known as MSD (short for Merck Sharp & Dohme) outside the United States and Canada, is set to significantly move up the rankings next year fueled by its cancer drug Keytruda, which witnessed a 55 percent increase in sales to US$ 11.1 billion. Merck reported total revenues of US$ 41.75 billion and also announced it will spin off its women’s health drugs, biosimilar drugs and older products to create a new pharmaceutical company with US$ 6.5 billion in annual revenues. The firm had anticipated 2020 sales between US$ 48.8 billion and US$ 50.3 billion however this week it announced that the coronavirus pandemic will reduce 2020 sales by more than $2 billion. View Our Interactive Dashboard on Top drugs by sales in 2019 (Free Excel Available) Humira holds on to remain world’s best-selling drug AbbVie’s acquisition of Allergan comes as the firm faces the expiration of patent protection for Humira, which brought in a staggering US$ 19.2 billion in sales last year for the company. AbbVie has failed to successfully acquire or develop a major new product to replace the sales generated by its flagship drug. In 2019, Humira’s US revenues increased 8.6 percent to US$ 14.86 billion while internationally, due to biosimilar competition, the sales dropped 31.1 percent to US$ 4.30 billion. Bristol Myers Squibb’s Eliquis, which is also marketed by Pfizer, maintained its number two position and posted total sales of US$ 12.1 billion, a 23 percent increase over 2018. While Bristol Myers Squibb’s immunotherapy treatment Opdivo, sold in partnership with Ono in Japan, saw sales increase from US$ 7.57 billion to US$ 8.0 billion, the growth paled in comparison to the US$ 3.9 billion revenue increase of Opdivo’s key immunotherapy competitor Merck’s Keytruda. Keytruda took the number three spot in drug sales that previously belonged to Celgene’s Revlimid, which witnessed a sales decline from US$ 9.69 billion to US$ 9.4 billion. Cancer treatment Imbruvica, which is marketed by J&J and AbbVie, witnessed a 30 percent increase in sales. With US$ 8.1 billion in 2019 revenues, it took the number five position. View Our Interactive Dashboard on Top drugs by sales in 2019 (Free Excel Available) Vaccines – Covid-19 turns competitors into partners This year has been dominated by the single biggest health emergency in years — the novel coronavirus (Covid-19) pandemic. As drugs continue to fail to meet expectations, vaccine development has received a lot of attention. GSK reported the highest vaccine sales of all drugmakers with total sales of US$ 8.4 billion (GBP 7.16 billion), a significant portion of its total sales of US$ 41.8 billion (GBP 33.754 billion). US-based Merck’s vaccine division also reported a significant increase in sales to US$ 8.0 billion and in 2019 received FDA and EU approval to market its Ebola vaccine Ervebo. This is the first FDA-authorized vaccine against the deadly virus which causes hemorrhagic fever and spreads from person to person through direct contact with body fluids. Pfizer and Sanofi also reported an increase in their vaccine sales to US$ 6.4 billion and US$ 6.2 billion respectively and the Covid-19 pandemic has recently pushed drugmakers to move faster than ever before and has also converted competitors into partners. In a rare move, drug behemoths — Sanofi and GlaxoSmithKline (GSK) —joined hands to develop a vaccine for the novel coronavirus. The two companies plan to start human trials in the second half of this year, and if things go right, they will file for potential approvals by the second half of 2021. View Our Interactive Dashboard on Top drugs by sales in 2019 (Free Excel Available) Our view Covid-19 has brought the world economy to a grinding halt and shifted the global attention to the pharmaceutical industry’s capability to deliver solutions to address this pandemic. Our compilation shows that vaccines and drugs for infectious diseases currently form a tiny fraction of the total sales of pharmaceutical companies and few drugs against infectious diseases rank high on the sales list. This could well explain the limited range of options currently available to fight Covid-19. With the pandemic currently infecting over 3 million people spread across more than 200 countries, we can safely conclude that the scenario in 2020 will change substantially. And so should our compilation of top drugs for the year. View Our Interactive Dashboard on Top drugs by sales in 2019 (Free Excel Available)

Impressions: 54755

Subscribe

Excel Download

#PharmaFlow by PHARMACOMPASS

29 Apr 2020

Share

Dead fish in Hyderabad puts pharma majors under scrutiny; False data uncovered in AstraZeneca’s US$ 4 billion buy

This week, Phispers has news from across the world. While China is trying to speed up approval of drugs by accepting data from overseas trials, the US achieved record approval of generic drugs last fiscal. In India, pharma companies may face legal action for releasing effluents into a lake in Hyderabad that killed thousands of fish last week. In France, a reformulated thyroid pill from Merck led to severe side effects in patients. And, there was more bad news for Israel’s Teva as its competitors won approvals from regulators in the US and Europe to market cheaper versions of its blockbuster multiple sclerosis drug — Copaxone. Data-integrity uncovered in AstraZeneca’s US$ 4 billion Acerta buy In February 2016, pharma giant AstraZeneca had invested US$ 4 billion in acquiring 55 percent stake in Acerta Pharma — a biopharmaceutical company based in the Netherlands and the US. The acquisition provided AstraZeneca with a cancer drug under clinical trials — acalabrutinib. An AstraZeneca press release issued at the time of acquisition had said: “Acalabrutinib is a highly selective, irreversible, second generation BTK inhibitor, with approximately 1,000 patients treated to date in clinical studies across the entire development programme.” But the acquisition brought some bad news for AstraZeneca last week, as a story published in Retraction Watch said one of Acerta’s former researchers had falsified early data on acalabrutinib. “The data, published as an abstract in August 2015 in the journal Cancer Research, reported a therapeutic benefit of acalabrutinib in a mouse model of pancreatic cancer,” the report said. The drug is now in human trials. Additional trials published in the New England Journal of Medicine and Blood in 2015 showed acalabrutinib had “promising safety and efficacy profiles in patients” with relapsed chronic lymphocytic leukemia. However, investigation into the data underlying the 2015 abstract revealed some of it was falsified. As a result, the journal retracted on the abstract. Interestingly a few weeks ago, acalabrutinib had won breakthrough therapy status at the US Food and Drug Administration (US FDA) along with an accelerated review plan for its first approval. However, all news was not bad news for AstraZeneca. Its innovative treatment for a type of lung cancer won “breakthrough” designation by the US FDA. The endorsement is for therapy Tagrisso for use in the US by patients with previously-untreated non-small cell lung cancer and a genetic mutation known as EFGR. This paves the way for fast-track approval of the drug. Dead fish in Hyderabad leads to pharma majors being booked for fouling lake water Pharmaceutical companies in India — such as Hetero Pharma, Aurobindo Pharm, Mylan, SMS Pharma, Vantec and Sriram — that have their manufacturing facilities in Kazipally industrial area and Industrial Development Area (IDA) have been booked under a case for “fouling water of public spring or reservoir”. This happened last week after the Gandigudem lake, which is barely a few meters away from Hyderabad's Outer Ring Road (ORR), reported hundreds of bloated, dead fish washed ashore after it rained heavily. The 266-acre lake is situated near the IDA. The lake has been plagued with pollution for a while now. According to news reports, the Pollution Control Board (PCB) had found traces of chloromethane, a solvent used in the pharma industry, in the samples of the water and dead fish collected from the lake. The diluted traces of the chemical in the lake confirm contamination. Officials said that 230,000 fish had been washed ashore within a span of two days, causing heavy loss to the fishermen dependent on the lake. According to an official, the fish lost was worth US$ 230,038 (Rs 15 million) These companies have been booking under Section 277 (fouling water of public spring or reservoir) and Section 278 (making atmosphere noxious to health) of the Indian Penal Code. A video of a news report on the story can be viewed here. China to accept data from overseas trials in order to speed up drug approvals China plans to speed up approval of drugs, and will accept data from overseas clinical trials in order to facilitate that. The move could be a boon for international drugmakers as well as for patients who often face lengthy delays for new medicines to reach the market. China has approved just over 100 innovative new drugs in the last 15 years — about a third of the drugs approved in the developed markets. This is the key reason behind the country taking this step to speed up drug approvals. The move also seeks to address high medicine costs, and improve access to healthcare for China’s 1.4 billion population. The Chinese Cabinet will also look into improving the protection of medical intellectual property and boost the number and quality of clinical trial testing centers in China. However, the proposals contained no timeline for implementation. In March this year, China had proposed ways to speed up approvals for imported drugs, including reforming clinical trial requirements. Merck’s French reformulation of most prescribed US drug leads to severe side effects Popular thyroid drug Levothyroxine reportedly received many complaints of severe side effects from patients in France. The drug works as a stand-in for the hormone thyroxine in patients suffering from hypothyroidism, a condition that affects the body’s metabolism. According to a Reuters report, French police searched German drugmaker Merck KGaA’s plant in Lyon last week as part of a probe into complaints by patients about changes to its thyroid drug Levothyrox. In March this year, Merck had removed lactose from Levothyrox to make it easier to tolerate and replaced it with citric acid and mannitol, a type of sugar alcohol. The new formulation had been requested by the French medicines regulator ANSM in 2012. According to patients, this resulted in severe side effects such as memory loss, hair loss, weight gain and palpitations. Around 3 million people in France, 80 percent of them women, use Levothyrox. According to a Medscape article, levothyroxin is also the most prescribed drug in the US. The prescriptions for Levothyroxine (in the US) stood at 112 million in 2012 and 123 million in 2016. The drug was far ahead of the number two drug on the list (Lisinopril — with 99 million prescriptions in 2012 and 110 million in 2016). Last month, a prosecutor in Marseille had launched a probe into whether Merck had deceived patients with the change in the drug’s formula. Since then, Merck has restored the original drug to the market. Teva fights to hold market share as competitors receive nod for its blockbuster drug Bad news from Israeli generic drug giant Teva Pharmaceutical Industries doesn’t seem to relent. Last week, Teva was taken unawares when its competitors won approvals from regulators in the US and Europe to market cheaper versions of its flagship Copaxone drug for multiple sclerosis. The launch of the competing products will result in “significant declines” in Teva’s largest product effective this year, Moody’s Investors service said in a note. On October 3, Mylan said it received approval from the US FDA for the marketing of generic versions of Teva’s Copaxone (glatiramer acetate) in 40 mg and 20 mg dosages. Mylan said it would start shipping the generic version immediately. According to Bernstein analyst Ronny Gal, Mylan is serving up 25 to 30 percent discounts versus the “prevailing price” on Teva’s Copaxone and Teva is countering it, he added. Analysts had written off Mylan’s long-delayed generic Copaxone until next year. The approval last week surprised analysts and investors. Two days later, Alvogen said it had received an approval from European regulators to market the 40 mg dose of generic Copaxone in Europe. Alvogen has been selling the 20 mg dose of the drug in Europe. These approvals could mean a “downside” to both revenue and profit estimates for 2018, Citi’s Liav Abraham said. Generic drug approvals in US hit all time high; Indian firms corner large chunk The US FDA approved a record 763 generic drugs in the US fiscal year that ended on September 30, 2017. Amongst these, Indian companies accounted for nearly 40 percent of the approvals, a news report published in the Mint said. The regulator also gave 174 tentative approvals during 2016-17. In comparison, the US FDA had approved 651 generic drugs last year, the latest Activities Report of the Generic Drug Program of the FDA said. Indian companies received a total of 295 product approvals in 2016-17. Amongst them, “the pace of drug approvals was strong for Aurobindo Pharma, Cadila Healthcare and Lupin,” the Mint report added. As per the FDA report, total filings of abbreviated new drug applications (ANDAs) for generic drugs with the US FDA rose to 1,292 in 2016-17 from 852 a year ago. According to analysts, the increasing number of product approvals and filings indicate an increase in competitive intensity in the US, which is a major market for many Indian drug companies. This would also result in more pressure on drug pricing.

Impressions: 3244

Subscribe

Excel Download

#Phispers by PHARMACOMPASS

12 Oct 2017

Share

India-China border tension may impact billion dollar pharma deal; AZ’s investors worry as key cancer drug fails trial

This week in Phispers, we analyze the situation at AstraZeneca, where its much anticipated lung cancer drug failed in clinical trials. In the US, there are reports that various generic players are looking to enter into M&A deals in order to safeguard themselves against regulatory crackdown on prices. The tension along the India-China border may lead to cancellation of the Fosun-Gland deal by the Indian government and in the US, the FDA is looking to cut nicotine in cigarettes to ensure they are non-addictive. AstraZeneca’s key lung cancer drug fails in first stage trial; gets investors worried The year 2017 was supposed to be a pivotal year for AstraZeneca. The firm was supposed to display new marvels from its laboratories and march towards annual revenues of US$ 45 billion by 2023. This target was set when Pfizer’s takeover offer was rejected in 2014. But so far, the year has turned out horribly for AstraZeneca. Its key lung cancer drug — Imfinzi — flopped in clinical trials. Known as the ‘Mystic’ study, this was the most anticipated clinical experiment in the pharmaceutical industry this year. The study was key to proving the value of the group’s new drug pipeline, after it rejected a US$ 118 billion takeover bid by Pfizer in 2014.The news crashed the share price of AstraZeneca by 15 percent. Imfinzi, an immuno-oncology drug, was said to be a potential replacement for chemotherapy. However, all is not lost yet. The first stage of the trial merely measured the drug’s ability to prevent a cancer from becoming worse. The second stage, which looks at survival rates, is said to be more important. But for Pascal Soriot, AstraZeneca’s CEO, this came as an embarrassment. He faced a barrage of questions from analysts about future payouts of the company. He was forced to defend the company’s dividend strategies at post-result meets last week. Fears for AstraZeneca’s dividend were driven by the failure of the lung cancer. But there is hope for Astra in the future — another lung cancer pill, Tagrisso, has produced good data. And AstraZeneca is partnering with Merck on another immuno-oncology drug, Lynparza. Another downside for Astra in 2017 has been the uncertainties faced by the company regarding its top executives. It began in January this year, when Luke Miels, the head of AstraZeneca’s European operations, announced he is quitting the company to join GlaxoSmithKline. Recently, there were speculations regarding Soriot considering an offer to join Israeli drugmaker Teva as its head. He is learnt to have turned down the offer. Bleak US generics market forecast has drug makers scrambling for deals In the US, generic drug makers are turning to M&As in order to safeguard themselves against a concerted effort by regulators to crack down on the steep prices of drugs. According to a Reuters report, Impax Laboratories, Perrigo and Alvogen have been talking to advisers about various strategic options for their generics businesses. These options range from acquisitions, as well as outright sale. Earlier, Reuters had reported that Mallinckrodt, one of the largest producers of the generic opioid painkiller oxycodone, has been exploring a sale of its specialty generics unit. In May, the CEO of Impax, which makes a generic version of the EpiPen allergy injection, said it was looking at deals. The US generics market is getting increasingly competitive. Last month, Novartis reported that sales at its Sandoz generics unit were down 4 percent. Generic drugs are cheaper versions of brand-name drugs. In the US, the government is targeting generics to cut the cost of prescription drugs. According to a 2016 report by the Journal of the American Medical Association, US consumers spend more than twice as much on drugs per capita compared to other industrialized nations. In order to bring down the prices of drugs, the US Food and Drug Administration (US FDA) has committed to eliminating the backlog of drug applications awaiting its approval. This could mean nearly 4,000 new drugs will come onto the market over the next few years, based on FDA estimates. Even today, small and mid-sized drug makers are under pressure as consolidation among generic drug distributors has made it less profitable for them to sell their drugs. India-China border skirmish may impact Fosun-Gland deal The heightened tensions along the India-China border are likely to impact business. In the pharmaceutical industry, the Cabinet Committee on Economic Affairs (CCEA) in India is likely to reject Shanghai Fosun Pharmaceutical Group’s US$ 1.3 billion acquisition of Hyderabad-based Gland Pharma Ltd, says a Bloomberg report. However, a report in The Economic Times says the proposal was listed for CCEA’s consideration two weeks back. But the CCEA is yet to take a call on the Gland Pharma-Fosun deal. “It is wrong to say that the deal has been rejected,” the official said. The Gland Pharma-Fosun deal had been approved by the now-abolished Foreign Investment Promotion Board (FIPB) in March this year. And Fosun was to acquire 86 per cent stake in the injectable drugmaker. According to IndiaSpend, China is today the 17th largest foreign direct investor in India, an improvement on the 36th rank it held in 2010. CRO Consolidation: LabCorp buys Chiltern, Evotec acquires Aptuit Consolidation in the CRO industry continued unabated last week. LabCorp bought Chiltern for US$ 1.2 billion last week. Two years back, LabCorp had bought Covance for US$ 6.1 billion. The acquisition of Chiltern will add another 4,500 clinical outsourcing workers around the globe to its employee roster. Another CRO that made an acquisition last week was Germany’s Evotec. It bought out its rival Aptuit for US$ 300 million in cash. And the deal will add hundreds of scientists to its organization along with facilities in Basel, Oxford and Verona. Evotec has earned a large number of clients on both sides of the Atlantic. Evotec says most of Aptuit’s 750 employees are scientists. Last year, Aptuit reportedly handled 1,000 projects for some 400 companies. The CRO business has been consolidating for years, with private equity groups leading the way to build up these global organizations. Leading the pack is Thermo Fisher, which had made acquisitions worth US$ 22 billion in the last five years. Three months back, Thermo Fisher Scientific acquired Patheon NV for US$ 5.2 billion while INC Research Holdings merged with private-equity owned CRO — inVentiv Health. FDA to cut nicotine in cigarettes to non-addictive levels Last week, the US government proposed cutting nicotine in cigarettes to “non-addictive” levels in order to move smokers towards potentially less harmful e-cigarettes. The FDA Commissioner Scott Gottlieb said the agency will study regulating nicotine levels with a view towards the “FDA’s potential to render cigarettes minimally addictive or non-addictive.” “Nicotine itself is not responsible for the cancer, the lung disease and heart disease that kill hundreds of thousands of Americans each year,” Gottlieb said. “It's the other chemical compounds in tobacco and in the smoke created by setting tobacco on fire that directly cause illness and death,” he added. The FDA cannot reduce nicotine levels to zero, nor can it ban cigarettes. However, after this announcement by Gottlieb, shares of major tobacco firms in the US and UK slumped. Analysts said they expect regulators in Europe to study similar actions on nicotine products. This action shakes up a public health debate on whether e-cigarettes represent a health risk or a potential benefit. NotPetya cyber attack hits Merck’s profits Merck is the latest in a string of companies that have disclosed that their operations were significantly disrupted by the NotPetya attack, which devastated businesses and government agencies in Ukraine in June and has gradually spread around the globe. According to a Reuters report, Merck said it had been a victim of an international cyber attack in June 2017, due to which the company had to halt production of drugs. As a result, its profits for the rest of the year have been hit. The company, however, said it is yet to know the magnitude of the impact as it is in the process of restoring manufacturing operations. Merck had disclosed the attack last month, but did not disclose the manufacturing shutdown at the time. The company said it was confident that it will be able to maintain a continuous supply of its top-selling and life-saving drugs, such as cancer drug Keytruda, diabetes drug Januvia and hepatitis C drug Zepatier. However, there maybe temporary delays in delivering some other products, which the company did not identify. “Full recovery from the cyber-attack will take some time, but we are making steady progress,” CEO Ken Frazier said. At least four other major US and European firms have also experienced massive outages due to NotPetya.

Impressions: 2566

Subscribe

Excel Download

#Phispers by PHARMACOMPASS

03 Aug 2017

Share

Find PharmaFlow Article for Osimertinib

Osimertinib

Osimertinib

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

23 API Suppliers

4 USDMF

4 EU WC

5 KDMF

6 NDC API

20 Listed Suppliers

DEVELOPMENTS

53 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

INTERMEDIATES

38 Suppliers

DOSSIERs // Finished Dosage Formulations

20 Dossiers

4 FDA Orange Book

4 Europe

2 Canada

4 Australia

2 South Africa

4 Listed Dossiers

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions

2 Finished Drug Prices

MARKET PLACE

7 APIs

2 DOSSIERS // FDF

PATENTS

20 US Patents

4 US Exclusivities

2 Health Canada Patents

DIGITAL CONTENT

3 Data Compilations & Company Tracker #PharmaFlow

129 News

1 Monthly Stock Recap #PipelineProspector

API SUPPLIERS

API REF. PRICE (USD / KG)

INTERMEDIATES

DOSSIERS // FDF

GLOBAL SALES (USD Million)

EXCIPIENTS

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

REF STANDARD

SERVICES

Top drugs and pharmaceutical companies of 2019 by revenues

Dead fish in Hyderabad puts pharma majors under scrutiny; False data uncovered in AstraZeneca’s US$ 4 billion buy

India-China border tension may impact billion dollar pharma deal; AZ’s investors worry as key cancer drug fails trial

What are you looking for?